Morten Brændengen

  • Head of section, consultant MD, PhD
 

Publications 2018

Brændengen M, Glimelius B (2018)
Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers
Radiother Oncol, 127 (3), 392-395
DOI 10.1016/j.radonc.2018.05.004, PubMed 29778486

Publications 2015

Guren MG, Kørner H, Pfeffer F, Myklebust TÅ, Eriksen MT, Edna TH, Larsen SG, Knudsen KO, Nesbakken A, Wasmuth HH, Vonen B, Hofsli E, Færden AE, Brændengen M, Dahl O, Steigen SE, Johansen MJ, Lindsetmo RO, Drolsum A, Tollåli G, Dørum LM, Møller B, Wibe A (2015)
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010
Acta Oncol, 54 (10), 1714-22
DOI 10.3109/0284186X.2015.1034876, PubMed 25924970

Publications 2014

Guren MG, Undseth C, Rekstad BL, Brændengen M, Dueland S, Spindler KL, Glynne-Jones R, Tveit KM (2014)
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395

Publications 2012

Radu C, Norrlid O, Brændengen M, Hansson K, Isacsson U, Glimelius B (2012)
Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients
Acta Oncol, 52 (3), 528-37
DOI 10.3109/0284186X.2012.737022, PubMed 23113591

Publications 2011

Brændengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B (2011)
Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study
Int J Radiat Oncol Biol Phys, 81 (4), e439-45
DOI 10.1016/j.ijrobp.2011.03.031, PubMed 21641122

Brændengen M, Tveit KM, Hjermstad MJ, Johansson H, Berglund Å, Brandberg Y, Glimelius B (2011)
Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study
Eur J Cancer, 48 (6), 813-9
DOI 10.1016/j.ejca.2011.06.035, PubMed 21782418

Publications 2010

Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund Å, Glimelius B (2010)
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study
Int J Radiat Oncol Biol Phys, 81 (4), 1017-24
DOI 10.1016/j.ijrobp.2010.07.007, PubMed 20932687

Publications 2008

Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, Wiig JN, Byström P, Bujko K, Glimelius B (2008)
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer
J Clin Oncol, 26 (22), 3687-94
DOI 10.1200/JCO.2007.15.3858, PubMed 18669453

Sørbye H, Braendengen M, Balteskard L (2008)
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
Tidsskr Nor Laegeforen, 128 (2), 194-7
PubMed 18202732

Publications 2004

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O (2004)
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer
J Clin Oncol, 22 (1), 31-8
DOI 10.1200/JCO.2004.05.188, PubMed 14701765

Publications 2003

Wiig JN, Waehre H, Larsen SG, Braendengen M, Giercksky KE (2003)
Radical prostatectomy for locally advanced primary or recurrent rectal cancer
Eur J Surg Oncol, 29 (5), 455-8
DOI 10.1016/S0748-7983(03)00030-1, PubMed 12798751

Publications 2002

Wiig JN, Poulsen JP, Larsen S, Braendengen M, Waehre H, Giercksky KE (2002)
Total pelvic exenteration with preoperative irradiation for advanced primary and recurrent rectal cancer
Eur J Surg, 168 (1), 42-8
DOI 10.1080/110241502317307562, PubMed 12022371

Publications 2000

Braendengen M, Bruland OS, Olsen DR (2000)
[Radiotherapy of skeletal metastases]
Tidsskr Nor Laegeforen, 120 (16), 1870-4
PubMed 10925615

Publications 1996

Braendengen M, Winderen M, Fosså SD (1996)
Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer
Br J Urol, 77 (1), 36-40
DOI 10.1046/j.1464-410X.1996.08467.x, PubMed 8653315

Page visits: 787